Our VHH-based ISOXTEND® technology protects biotherapeutics from kidney clearance by ‘piggybacking’ onto the serum albumin endocytic recycling pathway, significantly extending therapeutic...
CODON-PRECISE, SYNTHETIC, ANTIBODY FRAGMENT LIBRARIES BUILT USING AUTOMATED HEXAMER CODON ADDITIONS AND VALIDATED THROUGH NEXT GEN SEQUENCING Antibodies 2015, 4(2), 88-102
Ackaert et al review the immunogenicity risk profile of two VHHs from Phase II clinical trials, examining pre-existing ADAs and comparing to 3 months post-administration.
ANTI-LRP5/6 VHHS promote differentiation of WNT-hypersensitive intestinal stem cells Nature Communications 2019 10 (365)
Bao et al review the intersection between CAR-T development and VHHs against over a dozen tumour-associated antigens, with a focus on the bi-specific VHH therapy LCAR-B38M, now approved as CARVYKTI™.
In this poster from 7th CAR-TCR Summit in Boston, we discuss the power of VHHs in creating multi-specific ectodomains.
We explain the advantages of VHHs for CAR ectodomain targeting relative to traditional scFvs including size, solubility, and VHHs unique “magic finger” CDR3 domain.
The advantages of VHH in Neurodegenerative Diseases.
This whitepaper summarises the clinical and research landscape for CAR-T and T-cell engaging antibody therapies and show how single domain VHH antibodies can be applied to optimise the next generation of these important new therapeutic modalities.